IQVIA (IQV)
Health Care · Contract Research Organization (CRO) & Health Analytics · NYSE
IQVIA is a global leader in clinical research and healthcare data analytics that powers the development and commercialization of life-saving medical treatments.
What IQVIA does
IQVIA provides advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company operates by integrating clinical trial execution with healthcare data and information technology to help clients improve development and commercialization of new medicines.
Themes: clinical research services, healthcare data analytics, drug development optimization, life sciences technology, real-world evidence
Fundamentals
- Price$259.82 as of 2026-08-21 close
- Market cap$43.4B as of 2026-08-21
- 1-year return+40.1% 2025-08-21 close $185.39 → 2026-08-21 close $259.82
- P/E28.64 as of 2026-08-24
- Net margin+8.1% as of 2026-08-24
- Gross margin+33.0% as of 2026-08-24
- ROE+21.9% as of 2026-08-24
- Debt / equity2.59 as of 2026-08-24
- Revenue growth (YoY)+8.2% as of 2026-08-24
- Revenue CAGR (3y)+4.2% SEC XBRL
- Beta1.19 as of 2026-08-24
- Last reported earnings2026-07-28 SEC EDGAR Form 8-K (Item 2.02)
Dividend: at least 1 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How IQV compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
IQV is not currently in any published Top 10 list. Its scores are below.
Long-term score
47.5 #592 of 987 scored · #37 of 57 in Health Care
Long-term trend 80th (it is at or near its highest point of the past year) and profitability 55th (return on equity 22%, operating margin 12.9%); weakest is capital return (11th, consecutive years of dividend increases 1 year).
Short-term score
42.6 #1258 of 1,704 scored · #203 of 240 in Health Care
Trend 81st: it is trading 22.0% above its 50-day average, the short-term trend line; volume and participation 55th: trading volume is about normal versus its 30-day average; weakest is setup 27th: no Elliott-wave labelling currently fits its swings. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which IQV reported a dividend payment is FY2012, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2012 ratio would not describe IQV today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2012) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How IQVIA looks technically
IQVIA (IQV) is trading 29.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 11 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 73, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range. It is trading right at its highest price of the past year (its 52-week high).
Trend
9
| Distance from the 200-day | it is trading 29.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +29.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $212.96 | $212.96 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $200.44 | $200.44 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 227.15. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 11 trading days ago — a "golden cross", a bullish long-term signal | 11 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 29.6% above | +29.6% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control | 36.8 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 73, in overbought territory (above 70) | 72.7 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($227.15 to $260.40) — its "stochastic" reading is 98 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 98.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $260.40 | $260.40 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.2% |
| Above the 52-week low | it is 68.2% above its 52-week low (its lowest price of the past year) | +68.2% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.2% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $285.61 (set on 2021-12-30) | $285.61 |
| Given back of the 52-week move | over the past year its closes ranged ($156.66 to $259.82), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $192.77 to $196.07. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 9.0% below its all-time high | -9.0% |
| Nearest price level | it is trading 3.0% above a support level at $252.12 — a price it turned at twice since 2024-08-29, most recently on 2026-07-29. Since 2024-08-21 it has 16 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.0% |
| All-time low | its lowest closing price on record is $40.10 (set on 2013-10-31) | $40.10 |
| Above the all-time low | it is 547.9% above its all-time low | +547.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 41st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $8.30 between its high and its low — about 3.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $8.30 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $220.67 and $259.07 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $220.67 – $239.87 – $259.07 |
| Typical daily range (% of price) | its price moves about 3.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.2% |
| Stretch from the 200-day average | it is trading 7.2 daily ranges above its 200-day average price (29.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.94× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Open gap | it gapped 2.3% above the previous close 12 sessions ago and has not traded back through the level it left behind at 228.2 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.3% |
| Gap filled | a 2.5% gap down opened on 2026-07-21 has been "filled" 23 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 23 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +8.24% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 26.5 percentage points (the stock gained 28.9% while the market gained 2.3%) | +26.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 51.5 percentage points (the stock gained 54.6% while the market gained 3.1%) | +51.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 45.8 percentage points (the stock gained 56.9% while the market gained 11.1%) | +45.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 19.7 percentage points (the stock gained 40.1% while the market gained 20.5%) | +19.7% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 32% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.2% of the share price. | +31.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 37% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $190.18 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +36.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% above the average price paid since it last reported on 2026-07-28 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $241.72 — a volume-weighted average of daily closes over 19 sessions, not a true tick-by-tick VWAP. | +7.5% |
Price levels it has turned at before
IQV last closed at $259.82 on 2026-08-21. Since 2024-08-21 it has turned at 16 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $252.12 | Support | 3.0% below the last close | turned there twice · 2024-08-29 to 2026-07-29 |
| $246.41 | Support | 5.2% below the last close | turned there three times · 2024-09-19 to 2026-01-27 |
| $235.82 | Support | 9.2% below the last close | turned there twice · 2024-10-15 to 2025-11-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $227.15.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $258.14 and $308.28 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.38 mean, 1=Strong Buy…5=Strong Sell) — 18 analysts
- Mean price target$275.17 range $240.00 – $300.00; median $278.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IQV
- Consensus EPS estimate$3.27 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant debt levels and associated interest expense volatility.","Complex regulatory environment impacting clinical trial operations and data privacy.","High reliance on successful execution of large-scale clinical research projects."]
What changed in the latest 10-Q
AI-assisted comparison of IQV's 10-Q filed 2026-05-05 against the prior one filed 2025-10-28.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 'our 2025 Form 10-K' for fiscal year ended December 31, 2025 (newer filing, 2026-05-05)
- Description of segment restructuring effective January 1, 2026: Contract Sales & Medical Solutions incorporated into Technology & Analytics Solutions (renamed Commercial Solutions), and Real-World Late Phase offerings moved to another segment
- Statement about commitment to using artificial intelligence responsibly with specific phrasing about 'best-in-class approaches' (newer wording)
- Approximate employee count increased to 93,000 from 91,000 (newer filing, 2026-05-05)
- Removed:
- Reference to 'our 2024 Form 10-K' for fiscal year ended December 31, 2024 (older filing, 2025-10-28)
- Specific mention of 'COVID-19 (coronavirus) outbreak, including any variants' (older filing, 2025-10-28)
- Detailed description of three original reportable segments and their specific service offerings (older filing, 2025-10-28)
- Statement 'We are managed through three reportable segments' (older filing, 2025-10-28)
- Statement 'We do not have any material product revenues' (older filing, 2025-10-28)
- Approximate employee count of 91,000 (older filing, 2025-10-28)
- Reworded:
- AI commitment language changed from 'We are committed to using artificial intelligence ("AI") responsibly' to 'We are committed to using artificial intelligence responsibly' (removal of parenthetical abbreviation)
- Risk factor changed from 'business disruptions caused by natural disasters, pandemics such as the COVID-19 (coronavirus) outbreak, including any variants, and the public health policy responses to the outbreak, and international conflicts' to 'business disruptions caused by natural disasters, pandemics, and the public health policy responses to the outbreak, international conflict' (removal of specific COVID-19 reference and variants language)
- Risk factor wording changed from 'risks related to changes in accounting standards' to 'changes in accounting standards' (removed 'risks related to' phrase)
- Notes:
- The newer filing text appears truncated at the end of the Overview section, ending mid-sentence about Real-World Late Phase offerings
- The older filing also contains 'Sources of Revenue' section header which is not present in the newer excerpt provided
Risk Factors
- Reworded:
- Newer filing (2026-05-05) reports financial statements for three months ended March 31, 2026 and 2025; older filing (2025-10-28) reports for three months and nine months ended September 30, 2025 and 2024
- Newer filing balance sheet dated March 31, 2026 and December 31, 2025; older filing balance sheet dated September 30, 2025 and December 31, 2024
- Newer filing cash flows statement covers three months ended March 31, 2026 and 2025; older filing covers nine months ended September 30, 2025 and 2024
- Newer filing stockholders' equity statement shows activity for quarter ended March 31, 2026; older filing shows activity for nine months ended September 30, 2025
- Notes:
- The comparison involves different reporting periods (Q1 2026 in newer filing vs. Q3 2025 in older filing), which limits direct comparability of financial data
- The Risk Factors section header numbering changed from page 39 in older filing to page 32 in newer filing, but the actual Risk Factors content text is not provided in either source document for substantive comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 8 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 8 sells ($29M) — 5 selling insiders
- Last 90 days0 buys · 8 sells ($29M) — 5 selling insiders
- Last 180 days0 buys · 8 sells ($29M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-03. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IQV's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for IQV from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding IQV as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 24,901,694
- Reported value $4,246,734,976
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
IQV had 4,559,177 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
IQV had 2.73% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.72 days to cover at the same settlement.
- Reported short interest (shares) 4,559,177
- Short interest (% of shares outstanding) 2.73%
- Prior settlement (shares) 5,260,010
- Reported change -13.32%
- Days to cover (reported) 2.72
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- ICON (ICLR)
- Parexel
- Medpace (MEDP)
- Syneos Health
- Charles River Laboratories (CRL)
- Oracle Health (ORCL)
- Veeva Systems (VEEV)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IQV vs…
IQVIA is found in…
Frequently asked questions
What does IQVIA (IQV) do?
IQVIA provides advanced analytics, technology solutions, and clinical research services to the life sciences industry. The company operates by integrating clinical trial execution with healthcare data and information technology to help clients improve development and commercialization of new medicines.
What sector is IQVIA (IQV) in?
IQVIA (IQV) is classified in the Health Care sector. Its industry is Contract Research Organization (CRO) & Health Analytics. It trades on NYSE.
Who are IQVIA's (IQV) competitors?
Notable peers of IQVIA (IQV) include ICON, Parexel, Medpace, Syneos Health and Charles River Laboratories. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in IQV?
Yes — we hold 4 matched STOCK Act disclosures for IQV from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is IQVIA (IQV) overbought or oversold right now?
IQVIA (IQV) is currently in overbought territory (its 14-day RSI is 73, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IQV come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.